FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Novartis VC arm backs fledgling universal flu vax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

The venture arm of Novartis has joined a group of investors channeling $13.6 million in fresh funds for Immune Targeting Systems, which is hard at work on an experimental universal flu vaccine.

ITS said on Wednesday that the funds would allow researchers to push FP-01 through proof-of-concept studies, with Phase I studies kicking off this year. Its vaccine, one of a number of universal flu vaccines in the clinic, uses nanoparticles to deliver high density antigens to the immune system.

Sweden's HealthCap, Truffle Capital of France and London Technology Fund joined Novartis Venture Fund in the round. Their money brings ITS's Series A round to 13.15 million pounds.

"We believe strongly in the need to enhance T-cell immunity in vaccinology, and we are delighted that ITS is advancing its unique technology and lead program to clinical validation," says Florent Gros, managing director at Novartis Venture Fund.

- here's the press release
- check out the Reuters story

Related Articles:
Universal flu vax programs aim at blanket immunity
Universal seasonal flu jab could guard against pandemics


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Novartis   universal flu vaccine   biotech venture capital